Table 2.
In vitro genetic toxicology assays.
| OECD Test Guideline | Name | Endpoint | Comments |
|---|---|---|---|
| 471 (OECD, 1997a) | Bacterial reverse mutation test (Ames) | Gene mutation | |
| 473 (OECD, 2016c) | In vitro mammalian chromosomal aberration test | Clastogenicity | |
| 476 (OECD, 2016f) | In vitro mammalian cell gene mutation test (HPRT/XPRT) | Gene mutation | |
| 487 (OECD, 2016i) | In vitro mammalian cell micronucleus test | Clastogenicity / Aneugenicity | Kinetochore staining or MN sizing required to differentiate between clastogenicity and aneugenicity |
| 490 (OECD, 2016k) | In vitro mammalian cell gene mutation tests using thymidine kinase gene (MLA/TK6) | Gene mutation / Clastogenicity | Mutant colony sizing may differentiate clastogenic and mutagenic events |
| 472 (OECD, 2015) | Genetic toxicology: Escherichia coli, reverse assay | Gene mutation | Deleted by OECD (integrated into OECD 471) |
| 479 (OECD, 1986a) | Genetic toxicology: In vitro sister chromatid exchange assay in mammalian cells | Chromosome aberrations | Deleted by OECD |
| 480 (OECD, 1986a) | Genetic toxicology: Saccharomyces cerevisiae, gene mutation assay | Gene mutation | Deleted by OECD |
| 481 (OECD, 1986b) | Genetic toxicology: Saccharomyces cerevisiae, mitotic recombination assay | Mitotic recombination | Deleted by OECD |
| 482 (OECD, 1986c) | Genetic toxicology: DNA damage and repair, unscheduled DNA synthesis in mammalian cells in vitro | Unscheduled DNA synthesis | Deleted by OECD |
| In vitro comet assay | DNA damage | Not listed by the OECD but commonly used in the pharmaceutical sector |